<http://linked.opendata.cz/resource/sukl/spc/section/SPC127459_doc-4-9>	<http://salt.semanticauthoring.org/ontologies/sdo#hasSectionTitle>	"4.9 P\u0159ed\u00E1vkov\u00E1n\u00ED"@cs .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC127459_doc-4-9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://salt.semanticauthoring.org/ontologies/sdo#Section> .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC127459_doc-4-9>	<http://salt.semanticauthoring.org/ontologies/sdo#hasOrderNumber>	"004.009" .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC127459_doc-4-9>	<http://salt.semanticauthoring.org/ontologies/sdo#hasText>	"Nejsou \u017E\u00E1dn\u00E9 klinick\u00E9 zku\u0161enosti s masivn\u00EDm p\u0159ed\u00E1vkov\u00E1n\u00EDm. O\u010Dek\u00E1van\u00E9 ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky by m\u011Bly vztah k farmakodynamick\u00E9mu profilu agonist\u016F dopaminu, v\u010Detn\u011B nauzey, zvracen\u00ED, hyperkineze, halucinac\u00ED, agitace a hypotenze. Pro p\u0159\u00EDpad p\u0159ed\u00E1vkov\u00E1n\u00ED agonistou dopaminu nen\u00ED k dispozici \u017E\u00E1dn\u00E9 zaveden\u00E9 antidotum. Pokud jsou p\u0159\u00EDtomny p\u0159\u00EDznaky stimulace centr\u00E1ln\u00EDho nervov\u00E9ho syst\u00E9mu, m\u016F\u017Ee b\u00FDt indikov\u00E1no pod\u00E1n\u00ED neuroleptick\u00E9ho p\u0159\u00EDpravku. Zvl\u00E1dnut\u00ED p\u0159ed\u00E1vkov\u00E1n\u00ED m\u016F\u017Ee vy\u017Eadovat obecn\u00E1 podp\u016Frn\u00E1 opat\u0159en\u00ED spolu s\u00A0lav\u00E1\u017E\u00ED \u017Ealudku, nitro\u017Eiln\u00EDm pod\u00E1n\u00EDm tekutin, pod\u00E1n\u00EDm aktivn\u00EDho uhl\u00ED a monitorov\u00E1n\u00EDm elektrokardiogramu.\n"@cs .
<http://linked.opendata.cz/resource/sukl/spc/section/SPC127459_doc-4-9>	<http://salt.semanticauthoring.org/ontologies/sdo#hasParagraph>	<http://linked.opendata.cz/resource/sukl/spc/paragraph/SPC127459_doc-4-9-1> .